Type II mixed cryoglobulinemia in patients with Hepatitis C Virus: Treatment with pegylated-interferon and Ribavirin

Acta Medica Mediterranea

Volumn 31, Issue 3, 2015, Pages 651-662

  Malaguarnera, Michele ^a   Scuderi, Laura ^a   Ardiri, Annalisa ^a   Malaguarnera, Giulia ^a   Bertino, Nicoletta ^a   Ruggeri, Irene Maria ^b   Greco, Carmela ^a   Ozyalcn, Erdogan ^a   Bertino, Emanuele ^a   Bertino, Gaetano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b ARNAS Civic Hospital   (Italy)

Author keywords

Hepatitis C virus; Mixed cryoglobulinemia; Pegylated Interferon alpha 2a; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DEPRESSION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LEUKOPENIA; MALE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84957729536     PISSN: 03936384     EISSN: 22839720     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Choo QL, Richman KH, Han JH, Berger K, Lee C et al. Genetic organization and diversity of the hepatitis C virus Proc Natl Acad Sci USA1991. vol. 88, 2451-5.
2. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013 Sep; 10(9): 553-62. doi: 10.1038/nrgastro.2013.107. Review.
3. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002 vol. 36, 21-9.
4. Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013 Oct; 9(10): 1533-48. doi: 10.2217/fon.13.171. Review.
5. Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, Di Carlo I. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014; 2014: 203693. doi: 10.1155/2014/203693.
6. Bertino G, Demma S, Ardiri AL, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. Biomed Res Int. vol. 2015, 1-12; Article ID 731469, http://dx.doi.org/10.1155/2015/731469.
7. Biondi A, Malaguarnera G, Vacante M, Berretta M, D'Agata V, Malaguarnera M, Basile F, Drago F, Bertino G. Elevated serum levels of Chromogranin A in hepatocellular carcinoma. BMC Surg. 2012; 12 Suppl 1:S7. doi: 10.1186/1471-2482-12-S1-S7. Epub 2012 Nov 15.
8. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012 Aug; 39(4): 410-33. doi: 10.1053/j.seminoncol.2012.05.001. Review.
9. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
10. Ferri C, Zignego AL and Pileri SA Cryoglobulins (review). J Clin Pathol 2002. 55: 4-13.
11. Retamozo S, Brito-Zerón P, Bosch X, Stone JH, Ramos-Casals M. Cryoglobulinemic disease. Oncology (Williston Park). 2013 Nov; 27(11): 1098-1105, 1110-6. Review.
12. Bonnet F, Pineau JJ, Taupin JL, Feyler A, Bonarek M, de Witte S, Bernard N, Lacoste D, Morlat P, Beylot J. Prevalence of cryoglobulinemia and serological markers of autoimmunity in human immunodeficiency virus infected individuals: a cross-sectional study of 97 patients. J Rheumatol 2003, 30: 2005-2010.
13. García-Carrasco M, Ramos-Casals M, Cervera R, Trejo O, Yagüe J, Sisó A, Jiménez S, de La Red G, Font J, Ingelmo M. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 2001, 30: 366-373.
14. Ramos-Casals M, Cervera R, Yagüe J, García-Carrasco M, Trejo O, Jiménez S, Morlà RM, Font J, Ingelmo M. Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998, 28: 200-205.
15. Cicardi M, Cesana B, Del Ninno E, Pappalardo E, Silini E, Agostoni A, Colombo M. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat 2000, 7: 138-143.
16. Ramos-Casals M, Muñoz S, Medina F, Jara LJ, Rosas J, Calvo-Alen J, Brito-Zerón P, Forns X, Sánchez-Tapias JM HISPAMEC Study Group: Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases. J Rheumatol 2009, 36: 1442-1448.
17. Ferri C, Antonelli A, Mascia MT, Sebastiani S, Fallhai P, Ferrari D, Giunti M, Pileri SA and Zignego AL Bcells and mixed cryoglobulinemia. Autoimmun Rev 2007, 7: 114-120.
18. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: a metaanalysis. Hepatology. 2002 Oct; 36(4 Pt 1): 978-85.
19. Saadoun D1, Asselah T, Resche-Rigon M, Charlotte F, Bedossa P, Valla D, Piette JC, Marcellin P, Cacoub P. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology. 2006 Jun; 43(6): 1337-45.
20. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med. Jun 1966; 40(6): 837-56
21. Giuggioli D, Manfredi A, Colaci M, Manzini CU, Antonelli A, Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature Autoimmun Rev. 2013 Sep; 12(11): 1058-63. doi: 10.1016/j.autrev.2013.06.013.
22. Lee YH, Ji JD, Yeon JE, et al. Cryoglobulinaemia and rheumatic manifestationsin patients with hepatitis C virus infection. Annals of the Rheumatic Diseases1998; 57: 728-31.
23. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014 Jun 28; 20(24): 7544-54. doi: 10.3748/wjg.v20.i24.7544.
24. Ferri C, La Civita L, Fazzi P, Solfanelli S, Lombardini F, Begliomini E, Monti M, Longombardo G, Pasero G, Zignego AL. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol. 1997 Mar; 36(3): 360-5.
25. Wheeler RD, Sharma H, Groves M, Wren D, Sheldon J. A case study of mixed cryoglobulinaemia associated with peripheral neuropathy. Ann Clin Biochem. 2007 Nov; 44(Pt 6): 566-9.
26. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-8.
27. Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, Sarzi-Puttini P, Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol. 2008 Jan-Feb; 26(1 Suppl 48): S39-47.
28. Rockx MA and Clark WF Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci 42: 247-251, 2010.
29. Frankel AH, Singer DR, Winearls CG, et al Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 82: 101-124, 1992.
30. Zaja F, De Vita S, Mazzaro C, et al Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101: 3827-3834, 2003.
31. Quartuccio L, Soardo G, Romano G, et al Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45: 842-846, 2006
32. Cacoub P, Saadoun D, Limal N, et al PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005, 52: 911-915.
33. Leiner S. Peginterferon and ribavirin for hepatitis C. N Engl J Med 2007, vol. 356, no. 12, 1270.
34. Bertino G, Ardiri A.L., Boemi P.M., Calvagno G.S., Ruggeri I.M., Speranza A, Santonocito M.M., Ierna D, Bruno C.M., Valenti M, Boemi R, Naimo S, Neri S. Epoetin alpha improves the response to the antiviral treatment in HCV-related chronic hepatitis. Eur J Clin Pharmacol 2010, vol. 66, no. 10, 1055-63. doi: 10.1007/s00228-010-0868-4.
35. Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A, Ignaccolo L, Vadalà G, Misseri M, Maiorca D, Mastrosimone G, Judica A, Palermo F. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. J Clin Gastroenterol. 2010 Oct; 44(9): e210-7. doi: 10.1097/MCG.0b013e3181d88af5.
36. Malaguarnera M, Vacante M, Bertino G, Neri S, Malaguarnera M, Gargante MP, Motta M, Lupo L, Chisari G, Bruno CM, Pennisi G, Bella R. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J Interferon Cytokine Res. 2011 Sep; 31(9): 653-9. doi: 10.1089/jir.2011.0010.
37. Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Li Volti G, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol. 2011 Oct 21; 17(39): 4414-20. doi: 10.3748/wjg.v17. i39.4414.
38. Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G, Malaguarnera M. Acetyl-LCarnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepat Mon. 2014 May 5;14(5): e11608. doi: 10.5812/hepatmon.11608. eCollection 2014 May.
39. Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V, Zignego AL, Minerva N, Brindicci G, Marignani M, Baroni GS, Bertino G, Cuccorese G, Mottola L, Ripoli M, Pirisi M. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. PLoS One. 2014 Oct 23; 9(10): e110284. doi: 10.1371/journal.pone.0110284. eCollection 2014.
40. Malaguarnera M, Vacante M, Russo C, Gargante MP, Giordano M, Bertino G, Neri S, Malaguarnera M, Galvano F, Li Volti G. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients. Hepat Mon. 2011 Feb; 11(2): 92-8.
41. Bruno CM, Valenti M, Bertino G, Ardiri A, Amoroso A, Consolo M, Mazzarino CM, Neri S. Relationship between circulating interleukin-10 and histological features in patients with chronic C hepatitis. Ann Saudi Med. 2011 Jul-Aug; 31(4): 360-4. doi: 10.4103/0256-4947.83215.
42. Bruno CM, Valenti M, Bertino G, Ardiri A, Consolo M, Mazzarino CM, Amoroso A, Neri S. Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCVrelated chronic hepatitis. Relationship to histological features. Panminerva Med. 2009 Dec; 51(4): 191-6.
43. Bertino G, Ardiri AM, Calvagno GS, Boemi PM. In chronic viral hepatitis without malignancy, abnormal serum carbohydrate 19-9 antigen levels are associated with liver disease severity and are related to different viral aetiology. Dig Liver Dis. 2010 Jun; 42(6): 458-9. doi: 10.1016/j.dld.2009.09.011.
44. Bertino G, Ardiri AM, Calvagno GS, Malaguarnera G, Interlandi D, Vacante M, Bertino N, Lucca F, Madeddu R, Motta M. Carbohydrate 19.9 antigen serum levels in liver disease. Biomed Res Int. 2013; 2013: 531640. doi: 10.1155/2013/531640.
45. Zuckerman E, Keren D, Slobodin G, Rozenbaum M, Toubi E et al., Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha J Rheumatol 2000, vol. 27, 2172-2178.
46. Urraro T, Gragnani L, Piluso A, Fabbrizzi A, Monti M1, Fognani E, Boldrini B, Ranieri J, Zignego AL. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports Immunol. 2015;2015:816424. doi: 10.1155/2015/816424.
47. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest 2001; 31: 628-638.
48. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-374.
49. Gorevic PD, Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol 1991; 28: 79 94.
50. Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, Dammacco E Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998; 160: 3594-601.
51. Zignego AL, et al, for the Italian Association of the Study of Liver (A.I.S.F.) Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 38: 2-17.
52. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005; 5: 227-36.
53. Zignego AL, Macchia D, Monti M, Thiers V, Mazzetti M et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 1992; 15: 382-6.
54. Ferri C, Monti M, La Civita L, Longombardo G, Greco F et al. Infection of peripheral bloodmononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993; 82: 3701-4.
55. Sansonno D, IacobelliAR, CornacchiuloV, Iodice G, Dammacco F. Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. Clin Exp Immunol 1996; 103: 414-21.
56. Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012 May; 142(6): 1274-8. doi: 10.1053/j.gastro.2012.01.045
57. Yamane D, McGivern DR, Masaki T, Lemon SM. Liver injury and disease pathogenesis in chronic hepatitis C. Curr Top Microbiol Immunol. 2013; 369: 263-88. doi: 10.1007/978-3-642-27340-7-11. Review.
58. Li Y, Masaki T, Lemon SM. miR-122 and the Hepatitis C RNA genome: more than just stability. RNA Biol. 2013 Jun; 10(6): 919-23. doi: 10.4161/rna.25137.
59. Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M, Toro A, Malaguarnera M, Clementi S, Bertino N, Di Carlo I. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 2011 Oct; 102(5): 363-71. Review.
60. Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug News Perspect. 2010 Oct; 23(8): 498-508. doi: 10.1358/dnp.2010.23.8. 1444236. Review
61. Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 2006; 18: 54-63.
62. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia. A clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40: 837-56.
63. Levine JW1, Gota C, Fessler BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005; 32: 1164-1167.
64. Landau DA, Saadoun D, Halfon P, Martinot-Peignoux M, Marcellin P, Fois E, Cacoub P. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008; 58: 604-611.
65. Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, Carniello G, Virgolini L, Tirelli U, Pozzato G. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42: 632-638.
66. European Association for the Study of the Liver, EASL clinical practice guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011, vol. 55, no. 2, 245-264.
67. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. The New England Journal of Medicine, 2011 vol. 364, no. 13, 1195-1206. doi: 10.1056/NEJMoa1010494.
68. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine, 2011,vol. 364, no. 25, 2405-2416. doi: 10.1056/NEJMoa1012912.
69. Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, Piluso A, Caini P, Ranieri J, Monti M, Laffi G, Zignego AL. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Digestive and Liver Disease, 2014 vol. 46, no. 9, 833-837. doi: 10.1016/j.dld.2014.05.017
70. Saadoun D1, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Peg-IFN!/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases, 2014 vol. 73, no. 5, 831-83. doi: 10.1136/annrheumdis-2012-202770.
71. De Nicola S, Aghemo A, Campise MR, D'Ambrosio R, Rumi MG, Messa P, Colombo M. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antiviral Therapy, 2014vol. 19, no. 5, 527-531.
72. Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, Karras A, Bazin-Kara D, Cazorla C, Vittecoq D, Musset L, Peltier J, Decaux O, Ziza JM, Lambotte O, Cacoub P. PegIFN!/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Journal of Hepatology,2015 vol. 62, no. 1, 24-30. doi: 10.1016/j.jhep.2014.08.015.
73. Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med. 2015 Mar 7: 1-5.
74. Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015 Apr 24(4-5): 469-82. doi: 10.1177/0961203314556140.
75. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis. Am J Med. 2015 Mar 30. pii: S0002-9343(15)00252-1. doi: 10.1016/j.amjmed.2015.02.017. Review.